Avibactam Sodium Polymorphic Form, Pfizer, Apr 15
Summary
Pfizer Ireland Pharmaceuticals Unlimited Company has obtained publication of European patent application EP3505518A1 covering a polymorphic form of Avibactam Sodium (also known as NXL104), a beta-lactamase inhibitor with therapeutic applications classified under A61P 31/04 for anti-infective use. The application, published April 15, 2026, designates 41 states across the European Patent Convention framework and names eight inventors: Bhattacharya, Bonnet, Dedhiya, Ducandas, Giuliani, Priour, Ravaux, and Spargo.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
The European Patent Office has published patent application EP3505518A1 filed by Pfizer Ireland Pharmaceuticals covering a polymorphic crystalline form of Avibactam Sodium (NXL104), a beta-lactamase inhibitor compound. The application claims priority classifications in the C07D chemical compound series and specifies therapeutic use under A61P 31/04 (anti-infectives). The publication extends to 41 designated contracting and extension states under the European Patent Convention.
For pharmaceutical companies and drug manufacturers developing combination therapies incorporating beta-lactamase inhibitors, this publication establishes a public record of Pfizer's intellectual property position regarding specific crystalline forms of Avibactam Sodium. Competitors pursuing alternative polymorphs or salt forms should evaluate freedom-to-operate implications. Patent prosecution timelines and any subsequently granted claims will determine the scope of exclusivity.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
POLYMORPHIC FORM OF AVIBACTAM SODIUM (NXL104)
Publication EP3505518A1 Kind: A1 Apr 15, 2026
Applicants
Pfizer Ireland Pharmaceuticals Unlimited Company
Inventors
BHATTACHARYA, Sisir, BONNET, Alain, DEDHIYA, Mahendra G., DUCANDAS, Véronique, GIULIANI, Alexandre, PRIOUR, Alain, RAVAUX, Valérie, SPARGO, Peter
IPC Classifications
C07D 471/08 20060101AFI20190321BHEP A61K 31/439 20060101ALI20190321BHEP A61K 31/551 20060101ALI20190321BHEP A61P 31/04 20060101ALI20190321BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.